

**22 result(s) matched the criteria**([hide line-breaks](#))

<b>Institution Number</b>	<b>Protocol Full Title</b>	<b>Protocol PI Name - Full</b>
<a href="#">H0308089</a>	TMC 114-C202 / A Phase II Randomized Controlled, Partially Blinded, 48-Week Trial to Investigate Dose Response of TMC 114 /RTV in 3-Class Experienced, Multi PI-Experienced HIV-1 Infected Subjects	Katner, Harold P
<a href="#">H0312131</a>	Observational Cohort Study of Pneumonia in Fuzeon-Exposed and Non-Exposed Patients	Stephens, Jeffrey L.
<a href="#">H0406055</a>	A Multicenter, Randomized, Double-Blind Study on the Effects of Aripiprazole on Overweight Patients Treated with Olanzapine for Schizophrenia or Schizoaffective Disorder (CN138-122)	Shillcutt, Samuel D.
<a href="#">H0407066</a>	HIV Vertical Transmission and HAART (Highly Active Antiretroviral Therapy) Toxicity Study	Katner, Harold P
<a href="#">H0408070</a>	Rheumatoid Arthritis DMARD Intervention and Utilization Study (RADIUS 1)	Lynn, Kathy
<a href="#">H0409080</a>	TMC 114-C215: An Open Label Trial of TMC 114/RTV in HIV-1 Infected Subjects Who Failed Trial Treatment In The Sponsor Selected Trials With TMC 114	Katner, Harold P
<a href="#">H0409081</a>	Impact Study - A Phase IV, Multi-center, Cross-sectional study to evaluate the I50L Substitution Among Subjects Experiencing Virologic Failure on a HAART Regimen Containing Atazanavir (ATV)	Katner, Harold P
<a href="#">H0410093</a>	A Long-Term Open - Label Rollover Trial Assessing The Safety And Tolerability Of Combination Tipranavir And Ritonavir Use In HIV-1 Infected Subjects (Tipranavir 1182.17)	Katner, Harold P
<a href="#">H0410096</a>	A Randomized, Prospective Study Of The Efficacy, Safety, And Tolerability Of Two Doses Of GW 433908/Ritonavir Given With Abacavir/Lamivudine Fixed Dose Combination	Stephens, Jeffrey L.
<a href="#">H0502037</a>	Gemini Study - A 48-Week, Randomized, Open-Label, 2-Arm Study to Compare the Efficacy of Saquinavir/Ritonavir BID plus Emtricitabine/Tenofovir QD, in Treatment-Naive - HIV-1 Infected Patients (Protocol #ML 18413)	Katner, Harold P
<a href="#">H0503044</a>	TMC 114-C214: A Randomized, Controlled, Open-Label Trial to Compare the Efficacy, Safety, and Tolerability of TMC114/RTV versus LPV/RTV in Treatment-Experienced HIV-1 Infected Subjects	Katner, Harold P
<a href="#">H0506080</a>	Open-label safety study of TMC114 in combination with low dose ritonavir (RTV) and other antiretrovirals (ARVs) in highly experienced HIV-1 infected patients with limited or no treatment options.TMC114-C209	Katner, Harold P
<a href="#">H0506081</a>	Rheumatoid Arthritis DMARD Intervention and Utilization Study (RADIUS 2) Protocol 0616.0035	Lynn, Kathy

<a href="#">H0509105</a>	A Phase III Randomized, Double-Blinded, Placebo-Controlled Trial to Investigate the Efficacy, Tolerability, and Safety of TMC125 as Part of an ART Including TMC114/RTV and a Investigator-Selected OBR in HIV-1 Infected Subjects With Limited to no Treatment Options (Protocol TMC125-C206)	Katner, Harold P
<a href="#">H0511116</a>	Abbott Laboratories - M05-730 - A Phase 3 Randomized, Open Label, Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Daily Versus Twice Daily Administration, When Co-Administered With NRTIs in Antiretroviral HIV-1 Infected Patients	Katner, Harold P
<a href="#">H0511119</a>	TMC114-C226 Early Access of TMC114 in Combination with Low-Dose Ritonavir (RTV) and Other Antiretrovirals (ARV) in Highly Treatment Experienced HIV-1 Infected Subjects with Limited to No Treatment Options	Katner, Harold P
<a href="#">H0602015</a>	DECLARE 1 (Dexelvucitabine Compared to Lamivudine in Anti-Retroviral Experienced Subjects - 1) - INCB 08721-204	Stephens, Jeffrey L.
<a href="#">H0602018</a>	A Multicenter, Open-Label Study Evaluating the Safety and Efficacy of a New Investigational Protease Inhibitor (PI) with Fuzeon (Enfuvirtide) Plus Optimized Background in HIV-1 Infected Triple-Class Treatment Experienced, Enfuvirtide-Naive Patients (BLQ Study) - Protocol Number ML19712 -Ro 29-9800	Katner, Harold P
<a href="#">H0602019</a>	A Phase 2 Randomized Study of the Treatment of Antiretroviral Treatment-Experienced, HIV-1 Infected Subjects Comparing Ritonavir-Boosted GS-9137 (GS-9137/r) versus a Comparator Ritonavir-Boosted Protease Inhibitor (CPI/r) in Combination with a Background Antiretroviral Therapy GS-US-183-0105	Stephens, Jeffrey L.
<a href="#">H0604028</a>	A Randomized, Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of the Combination of Valsartan/HCTZ/Amlodipine Compared to Valsartan/HCTZ, Valsartan/Amlodipine, and HCTZ/Amlodipine In Patients With Moderate to Severe Hypertension (CVEA489A2302)	James, Erskine A.
<a href="#">H0604047</a>	A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin (Ezetimibe/Simvastatin Tablet) vs. Simvastatin Monotherapy in High-Risk Subjects Presenting with Acute Coronary Syndrome (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial - IMPROVE IT) Protocol No. P04103	Hudson, John A
<a href="#">H0605056</a>	TMC125-C217 An Open-Label Trial with TMC125 as part of an ART Including TMC114/RTV and Investigator-Selected OBR in HIV-1 Infected Subjects Who Participated In A DUET Trial (TMC125-C206 or TMC125-C216)	Katner, Harold P
<b>22</b>	<b>22</b>	<b>22</b>